Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07660094 · ClinicalTrials.gov registry record · Phase 3
Aglatimagene Besadenovec + Prodrug and Pembrolizumab vs Docetaxel for Stage IV Non-Squamous NSCLC Progressing on Pembrolizumab (AURORA)
A Phase 3 study, sponsored by Candel Therapeutics.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 500
- Enrollment target
NCT07660094 is a Phase 3 study that is actively recruiting participants, run by Candel Therapeutics. The registered enrollment target is 500 participants.
The verdict
NCT07660094, a Phase 3 study, is actively recruiting participants, sponsored by Candel Therapeutics.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 500 participants
- Enrollment target
Study Summary
This phase III trial compares the effect of the combination of aglatimagene besadenovec and pembrolizumab versus standard of care docetaxel chemotherapy for the treatment of stage IV non-squamous, non-small cell lung cancer. Aglatimagene besadenovec is a replication-deficient adenoviral vector encoding the herpes simplex virus thymidine kinase (HSV-tk) gene. When combined with an oral prodrug (valacyclovir), injection of aglatimagene induces targeted tumor cell death and stimulates a systemic immune response. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. This trial may help doctors find out if giving aglatimagene with pembrolizumab is more effective at treating patients with stage IV non-squamous, non-small cell lung cancer than standard chemotherapy.
Interventions
- BIOLOGICAL Pembrolizumab
- DRUG Docetaxel
- DRUG Valacyclovir
- BIOLOGICAL Aglatimagene Besadenovec
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 500 participants |
| Start Date | 2026-06-15 |
| Est. Completion | 2031-10-22 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07660094
The ClinicalTrials.gov registry entry for NCT07660094 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 500 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Candel Therapeutics, which has 13 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Pembrolizumab is the first listed.
NCT07660094 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07660094 about?
NCT07660094 is a clinical study titled "Aglatimagene Besadenovec + Prodrug and Pembrolizumab vs Docetaxel for Stage IV Non-Squamous NSCLC Progressing on Pembrolizumab (AURORA)". This phase III trial compares the effect of the combination of aglatimagene besadenovec and pembrolizumab versus standard of care docetaxel chemotherapy for the treatment of stage IV non-squamous, non-small cell lung cancer. Aglatimagene besadenovec is a replication-deficient adenoviral vector encod...
What is the current status of trial NCT07660094?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 500 participants. The study started on 2026-06-15. Estimated completion is 2031-10-22.
What interventions are being tested in trial NCT07660094?
The interventions under investigation include: Pembrolizumab (BIOLOGICAL), Docetaxel (DRUG), Valacyclovir (DRUG), Aglatimagene Besadenovec (BIOLOGICAL).
Who is sponsoring clinical trial NCT07660094?
This trial is sponsored by Candel Therapeutics, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.